Dataset Information

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141⁺ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8⁺ T Cell Response in Human Immune System Mice.

ABSTRACT: Active co-delivery of tumor antigens (Ag) and α-galactosylceramide (α-GalCer), a potent agonist for invariant Natural Killer T (iNKT) cells, to cross-priming CD8α⁺ dendritic cells (DCs) was previously shown to promote strong anti-tumor responses in mice. Here, we designed a nanoparticle-based vaccine able to target human CD141⁺ (BDCA3⁺) DCs - the equivalent of murine CD8α⁺ DCs - and deliver both tumor Ag (Melan A) and α-GalCer. This nanovaccine was inoculated into humanized mice that mimic the human immune system (HIS) and possess functional iNKT cells and CD8⁺ T cells, called HIS-CD8/NKT mice. We found that multiple immunizations of HIS-CD8/NKT mice with the nanovaccine resulted in the activation and/or expansion of huma

SUBMITTER: Huang J

PROVIDER: S-EPMC7461784 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature

ACCESS DATA

Dataset Information

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141⁺ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8⁺ T Cell Response in Human Immune System Mice.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Dataset Information

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141+ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8+ T Cell Response in Human Immune System Mice.

OmicsDI is part of the ELIXIR infrastructure

Tweets

Targeted Co-delivery of Tumor Antigen and α-Galactosylceramide to CD141⁺ Dendritic Cells Induces a Potent Tumor Antigen-Specific Human CD8⁺ T Cell Response in Human Immune System Mice.